The Next Super Bug | DAVOS 2020

TL;DR

The emergence of new and drug-resistant infectious diseases poses a global threat, requiring preparedness, trust-building, and collaboration.

Transcript

we should invent powerful antibiotics versus different pathogens and then we should put them in a closet with a glass cover and only to be broken in case of an emergency but rather not use it because it is the over usage of antibiotics which is now leading again through evolution to resistance and leaves us in a very very vulnerable situation we ha... Read More

Key Insights

• 🌐 Epidemic diseases are an inherent structural threat to society due to global travel and interactions with wildlife.
• 😵 Preparedness for epidemics requires cross-border collaboration, transparency, and the development of rapid countermeasures.
• 😣 Antimicrobial resistance poses a slow-moving but severe threat, necessitating the development and responsible usage of powerful antibiotics.
• 🧑‍⚕️ Vaccine hesitancy, driven by societal and political factors, contributes to global health crises and requires rebuilding trust and countering misinformation.
• 👨‍🔬 Governments, private sectors, and philanthropic organizations need to collaborate and invest in preparedness, research, and regulatory improvements.
• 🌱 Individual and community actions, such as preparedness plans, communication networks, and reducing dependence on mobile devices, can contribute to resilience.
• 🧑‍⚕️ Cooperation and collaboration are essential for addressing public health emergencies and building trust between nations and communities.
• 🔒 The private sector, particularly the pharmaceutical industry, can contribute through funding, technological advancements, and adhering to accessible drug models.

Questions & Answers

Q: How likely are newly emerging epidemic diseases to become global threats, and are we prepared to respond?

The increasing number of epidemic threats is a real phenomenon caused by how societies are organized and the speed of global travel. Preparedness requires cross-border collaboration, transparency, and the development of rapid countermeasures like vaccines.

Q: Why is antimicrobial resistance a pressing issue, and what can be done to combat it?

Antimicrobial resistance is a slow-moving but potentially catastrophic threat to humanity. To address it, powerful antibiotics need to be developed and preserved, with a focus on responsible usage and the allocation of resources for research, development, and regulatory process improvements.

Q: How does vaccine hesitancy contribute to global health crises, and what should be done to combat it?

Vaccine acceptance is crucial in preventing the spread of diseases and mitigating the risk of antimicrobial resistance. Societal and political factors, as well as increased uncertainty and questioning of authority, contribute to vaccine hesitancy. Rebuilding trust, improving vaccine education, and countering misinformation are essential in combating this issue.

Q: What is the role of the private sector, particularly the pharmaceutical industry, in addressing public health emergencies?

While the pharmaceutical industry is not solely responsible, it can play a crucial role in addressing public health emergencies. Collaboration is key, with companies providing funding, expertise, technology, and adhering to a subscription model where drugs are made available even if not used, ensuring their accessibility for ordinary people.

Summary & Key Takeaways

• Epidemic diseases are on the rise due to factors like increased global travel and interactions with wildlife species, making them a structural threat to society.

• Antimicrobial resistance is a serious and urgent threat, as it can render current antibiotics ineffective and jeopardize medical interventions.

• Vaccine hesitancy, fueled by misinformation and distrust, contributes to global health crises and the spread of preventable diseases.